To the Editor:
Human cell lines are central to biomedical research and medicine, but genetic evolution and inconsistencies among derived lineages are too often ignored. These issues are becoming increasingly important now that wide adoption of gene editing technologies like CRISPR has led to a boom in the development of new genetic lineages with knock-in reporters or patient-specific mutations (Fig. 1a). A more detailed view of cell line provenance and lineage formation can guard against wasted research effort and funds and, ultimately, improves reproducibility of biological research. Accurate cell line tracking is also required for safely establishing cell therapies as part of precision medicine.
Fig. 1 ∣.
Genome reading and writing technologies have contributed to an expansion in the number of cell lineages and advanced methods to characterize and track these lineages. (a) Historically, limited numbers of unique cell lines were used. Lineage tracking was minimal, resulting in a knowledge vacuum on cell-line provenance (left). Biomedicine requires ever-larger cell-line panels representing more patients (grey circles), tissues and diseases. For each cell line, lineages diverge during in vitro maintenance and manipulation (blue arrows). Genetic differences may be consciously engineered, but also occur stochastically (right). The latter are unconsciously influenced by laboratory practices including passaging. (b) Evolution experiments with clonal microorganisms involve parallel propagation of initially identical cell populations. Each is passaged and sequenced regularly to evaluate stochastic genetic and phenotypic divergence (lineage A–E). (c) Evolution experiments may show ‘rich-get-richer’ effects, where fitness benefits compound over time, and ‘leap-frog’ events, in which lineages with beneficial genetic changes outgrow ones without7. Rich-get-richer dynamics were modeled using 10%-fitness gains per five doublings and a passage-13 leap-frog event with a four-fold doubling-speed increase. (d) Somatic cells commonly accumulate stochastic genetic changes over human lifetimes, forming distinct cell lineages by middle age. Although most changes are deleterious or nearly neutral for individual cells, some confer growth or survival benefits and will occasionally contribute to age-related diseases at the whole-organism level. For example, hematopoietic stem cells carrying TP53 mutations increase risk for acute myeloid leukemia9.
Currently, 18-36% of common cell lines are estimated to be mislabeled or contaminated, and in addition, cell lines often evolve divergent lineages1,2. Cell lineages can form by spontaneous or induced selection events during cell culture, or when cells are genetically modified. Although funders and journals are starting to acknowledge the importance of cell-line authentication, cell-lineage provenance is rarely recorded or published, despite its major impact on data reliability and reproducibility3-5.
Here, we discuss lineage divergence as a natural, inevitable phenomenon across all kingdoms of life. We highlight how lineage formation in human cell culture is influenced by routine laboratory practices and has accelerated in the genomics and gene-editing era. We also propose simple changes to current working routines to minimize unwanted lineage divergence. Lastly, we explore how monitoring divergence can be helpful in certain cases for obtaining new biological insights.
Lineage formation is ubiquitous in all kingdoms of life
Across life, stochastic genetic changes in clonally proliferating cells lead to de novo lineage formation, affecting both asexually reproducing organisms and somatic cells of sexually reproducing organisms. Long-term evolutionary monitoring of asexual microbe populations, including bacteria and yeast, has yielded critical insights into lineage formation dynamics6 (Fig. 1b). Lineation can accelerate when stochastic genetic changes result in competitive fitness variation, defined as the time needed for one cell doubling. Although most genetic changes are deleterious or nearly neutral, cells that acquire beneficial genetic changes may outcompete other cells by improved fitness and take over the population. Fitness gains can occur via 1) ‘rich-get-richer’ effects, a beneficial genetic change in a cell drives steady clonal expansion, increasing chances that additional changes are accrued, or 2) leap-frog events, a genetic change confers an immediate, sizeable fitness benefit to a cell, leading to sudden clonal expansion7, possibly through emerging epistatic fitness benefits in conjunction with prior changes (Fig. 1c).
Lineage formation also occurs naturally in somatic tissues of multicellular organisms including plants and animals8. It is the driving force of genetic mosaicism and can strongly affect organismal phenotypes. In vivo genetic changes in human tissues result in lineage formation and aging-related mosaicism, such as clonal hematopoiesis. Here, hematopoietic stem cell lineages accumulate anomalous de novo genetic changes, which can drive detrimental health outcomes (Fig. 1d)9. For example, changes in the JAK2 gene can lead to a 12-fold increase in coronary heart disease risk9. Even more dramatic, ~8% of elderly men carry cell lineages without a Y chromosome, which may reduce lifespan by 5.5 years10. In cancer, lineage divergence is at the root of complex, genetically heterogeneous tumors. Selection induced by targeted cancer therapies can cause intra-tumor lineage evolution with cells escaping therapy regimes, leading to cancer recurrence11.
When lineage formation occurs in cells or organisms that live in environments under human management, both natural and human-mediated selection will act on phenotypic differences. Charles Darwin divided human-mediated selection into conscious and unconscious selection. Conscious selection can be an important driving force in human cell culture, for instance when researchers select cell lineages with increased production of a desired protein12,13. However, researchers also unconsciously apply selection pressure on doubling-time differences between cultured cells. In vitro-cultured human cells will gradually accumulate differences in this competitive fitness metric, similar to the above-mentioned microorganisms and somatic cells. Unconscious selection operates continuously and is influenced by researchers’ everyday decisions (Fig. 2).
Fig. 2 ∣. Evolutionary dynamics and selection in cell-line establishment and maintenance.
Clonally-proliferating cells experience fluctuations in cell density due to population expansion (seeding to confluence) and contraction during sub-culturing (passaging). In addition, each doubling introduces risk of cells acquiring single-nucleotide or larger changes, such as aneuploidy (circled numbers). Beneficial genetic changes (shortening doubling times) will be selected and sweep through the population, creating divergence between a cell lineage and its ancestors. (a) The Muller plot shows an example of clonal cell expansion with serial stochastic genetic changes under positive selection resulting in new sub-lineages. (b) Passaging of a cell mixture from (a) after confluence (rightmost time-point in panel a). The cell population is passaged via dilution (e.g., 1:5 split ratio). Assuming perfect mixture, split cell populations have similar levels of sub-lineage heterogeneity at seeding. When independent de novo genetic changes with fitness benefits continue to accumulate (change number 5), this results in further lineage divergence into distinct sub-lineages–observe emergence of the light blue sub-lineage in ‘Lineage A,’ creating divergence between Lineage A and ‘Lineage B’. These distinct lineages may have distinct phenotypes. (c) Isolation of a single cell from (a) at confluence (rightmost time-point in panel a). Isolation of single cells for clonal expansion introduces genetic bottlenecks and can result in unintended isolation of sub-lineages: compare heterogeneous Lineage A and Lineage B with monoclonal expansion of ‘Lineage C’ and ‘Lineage D’. For example, the dark-grey sub-lineage in Lineage A can thrive as monoclonal lineage in Lineage C, but would otherwise have disappeared.
Evolution of human cell lineages during routine cell culture
Evolution drives lineage divergence in all cell types and can strongly affect cellular phenotypes and experimental outcomes. Although cancer cell lines are especially at risk due to their inherent genetic instability5, similar patterns are observed in other in vitro-grown cell types, such as pluripotent stem cells14-17.
Perhaps the best-known example of lineage formation and divergence in cultured cells is HeLa3. This genetically unstable cervical cancer cell line has been propagated, split and shared among thousands of laboratories since 1951. Analysis of 13 HeLa lineages for genetic and phenotypic differences showed that individual lineages accumulated unique genetic changes after 7–50 passages and chromosome segments varied from one to six copies per cell3. Despite considerable genetic divergence, all independently evolving lineages are referred to in publications as ‘HeLa cells’. Only occasionally are major ancestral lineages, CCL2 or Kyoto, mentioned — and even then, no information on recent pedigree branching or passage number is provided. The phenotypic consequences of lineation include extreme variance in cell doubling time between lineages under identical culture conditions (18–33 hours) and discordance in susceptibility to pathobiont infection3.
Similarly, lineage formation has been observed for the MCF-7 breast cancer and human embryonic kidney 293 (HEK293) cell lines, leading to substantial phenotypic differences between the different cell lineages4,5, including differences in drug response5, the ability to grow in suspension4,12, and gene expression12.
An analysis of 1,700 lineages from 259 embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) found that ~13% of lineages are aneuploid15. Recurrent amplifications of chromosomes 8, 12, 17, 20 and X appear to cause leap-frog events (Fig. 1c) because fitness jumps often occur within 10 passages with up to threefold selective growth advantages14,15,18.
For iPSCs, reprogramming is regularly accompanied by chromosomal amplifications and, overall, iPSCs show similar risk of forming aberrant cell lineages as ESCs14,15.
Factors impacting cell lineage formation
Several steps and factors in daily laboratory workflows contribute to cell-lineage formation and divergence, including cell-line establishment, passaging protocols, passage number at the time of an experiment, choice of cell culture media, and freeze-thaw frequency.
The initial steps of cell culture involve a drastic environmental change: cells of all types must adapt to growing in two-dimensional (2D) cell-culture environments instead of complex three-dimensional (3D) tissues in vivo. In these early steps, aneuploidy may confer fitness benefits. A >50% improvement in survival was observed in vitro for ESCs that adapted through specific chromosomal amplifications17. Furthermore, the frequency at which a specific genetic alteration occurs in a tumor versus in cell culture can differ19. For example, gain of chromosome segment 3q25-27, which is found in 17% of live tissue samples (n=356), was detected in only 9% of cultured non–small cell lung cancer cell lines (n=86)20.
Passaging choices involve fine-tuning of parameters to maintain optimal cell viability and genetic stability18 (Fig. 2a,b). For stem cells, cell dissociation can be important. For example, enzymatic dissociation disrupts cell–cell contact, which can lead to karyotypic changes18 or a type of apoptosis called anoikis (‘homeless’). Anoikis occurs via cytoskeleton contraction in an isolated cell, activated through Rho-associated kinase (ROCK)-mediated phosphorylation. Although potentially deleterious, full cellular dissociation is required in certain protocols, for example when establishing monoclonal lineages after genetic engineering. Viable clones derived from single cells experience a genetic bottleneck (Fig. 2c), a risk for any cell type, and thus require characterization. In contrast, full dissociation and subsequent mixing during cell passaging preserves genetic diversity more evenly. The anticipated frequency of anoikis is (unconsciously) factored into decision-making, as dissociative passaging protocols typically recommend 1:1 to 1:5 instead of 1:50 dilutions. An alternative passaging method involves clumped/clustered cell transfer, which maintains cell–cell adhesion. This method minimizes aneuploidy and anoikis21, and is frequently used for stem-cell maintenance. However, with clumped transfer, anomalous genetic changes in transferred cells might be more likely to establish in the descendant cell lineage.
Cell passage number is indicative for the extent of lineage divergence1,3,5,12,13. For example, in a model for human intestinal epithelium (Caco-2), lineages with added passages showed decreased doubling times, affecting cellular monolayer permeability and drug transport properties1. This means between-study variation in experimental results can arise because parallel lineages of the same cell line are compared at different passages. Because these patterns are observed across cell types1,3,5-7,12,14,15, and may be unavoidable during continuous culturing, cell passage number and doubling speed should be recorded so researchers can compare between experiments.
Media choice can also alter adaptive characteristics of cell survival and growth. ROCK inhibition reduces cytoskeletal contraction during dissociative passaging and promotes cell survival16. Inhibitors are therefore widely used during dissociation and single-cell cloning steps of ESC/iPSC culture protocols. However, because cells with highly deleterious genetic changes can be removed through apoptosis, blocking this with ROCK inhibitors may increase the risk of selecting novel lineages with aberrant genetic changes. Media regimens are further used to direct cell adaptation for specific characteristics. For example, the HEK293F lineage, cultured for factor VIII production to treat hemophilia13, was adapted to serum-free suspension culture from a fast-growing adherent clone. This consciously selected lineage is now considered stable for this phenotype and can be distinguished from related lineages through gene expression profiling12.
Freezing cell populations at specific passages allows researchers to halt ongoing lineage formation and assay specific passages along a lineage (Fig. 1a). We have shown the viability of this approach by performing high-throughput sequencing on a DNA-barcoded mouse cancer cell line before and after freeze-thaw, finding cell barcode distributions were preserved after recovery (r2 ~0.9)22. However, caution is warranted, as freeze-thawing could still pose a genetic bottleneck when working with some cell lines or lineages. Indeed, the genetic copy number profile of HEK293S-lineage cells shifted over a freeze-thaw step4. Cells that survive freeze-thaw and outcompete others determine the genetic make-up of the thawed population, leading to changes in doubling time and other traits. Doubling times of recently thawed cells may continue to change during additional passaging4,5.
This is a subset of daily laboratory routines influencing in vitro lineage formation and divergence. Researchers should take measures to monitor and minimize lineage divergence in cell lines during routine culturing (Table 1), which is important given the recent increase in derivation of new cell lines and lineages.
Table 1.
Roadmap for routine cell tracking.
| Step | Action | Methods |
|---|---|---|
| Start | Create a journal devoted to cell lines used in your laboratory. | Create a designated cell-tracking workbook using Google Sheets. One of us (S.Z.) has recently started a company (FIND Genomics) to develop specialized cell-tracking software that integrates laboratory record-keeping with genome sequencing using low-pass whole-genome sequencing (WGS). |
| Track | Record daily routine steps. | Write down time between passages, total Days In Vitro (DIV), splits, use of specific media, treatments, protocols or modifications, as well as observations on cell doubling time and cell health. |
| Track individual cell lineages. | When a cell population is passaged (split) from a single to multiple culture flasks, track ongoing passaging separately for each individual new lineage. | |
| Record which cell population you used in an experiment. | Mark usage of a specific cell population used in an experiment. Indicate which cell lineage the cell population is part of. | |
| Assess lineages for the presence of Mycoplasma infection. | Record which cell populations are tested for Mycoplasma within each lineage. This allows tracing back which cell lineages are at risk, and which ones can be salvaged. | |
| Genotype | Periodically authenticate cell populations from specific lineages. | Assess short tandem repeat (STR) or single nucleotide polymorphism (SNP) markers offered by service providers. Alternatively, perform/use low-pass WGS for matching your cell population to your cell-line database. Depending on experimentation intensity this should ideally be performed once every 15 passages. High risk cell lines are listed by the International Cell Line Authentication Committee (ICLAC). |
| Periodically determine genetic stability of cell lineages. Note: especially needed after creating novel monoclonal lineages. |
Analysis of genetic stability of cell populations can be meaningful at various levels of resolution: karyotype-, copy number-, mutation-, or site-specific changes. The resolution required will depend on cell type and experimental goals. The chosen resolution will determine the cost of data collection per sample using low-pass WGS or other assays. Record the passage number and the resolution of the test performed at the time of testing. |
|
| Detection of off-target effects from CRISPR engineering. | Use WGS or specialized methods like breaks labeling in situ and sequencing (BLISS) or circularization for in vitro reporting of cleavage effects by sequencing (CIRCLE-seq). | |
| Share | Record all exchanges of cell lines with other laboratories. When intending to repeat an experiment from a particular laboratory, ask this laboratory for cells from the exact same lineage used in the published experiment(s). In this manner, discrepancies between experiments can be traced back to a particular lineage or passage number. |
Ask the providing laboratory to share a cell lineage’s passage number and history (e,g, information from Track and Genotype above). |
| Verify lineage evolution to ensure possible experimental discrepancies are not due to lineage divergence. | Compare cell doubling time and genetic stability for cells currently in culture with the original cell population from the originating laboratory. | |
| Search and update | Register any new cell lines or genetically distinct cell lineages (formed through conscious or conscious selection). | Examples of public cell databases are hPSCreg or Cellosaurus. |
Accelerated lineage formation in the genomics and gene-editing era
Over the past decade, new genome engineering technologies have made it straightforward to knock-out or tag genes and insert putative disease variants21. Given the rapid adoption of genome editing tools, the boom in new cell lineages is poised to continue (Fig. 1a). New lineages can be derived by engineering genetic changes using programmable nucleases (e.g. zinc-fingers, TALENs, and CRISPR-Cas proteins), integrating transposons, viral vectors or plasmids4.
CRISPR-mediated gene disruption and homology-directed repair now make it straightforward to perform precise knock-ins in most human cell lines23,24. Although CRISPR nucleases have accelerated the pace of genome editing, they can also induce off-target genetic changes25, which necessitate careful monitoring by whole-genome sequencing, targeted sequencing of predicted off-targets and/or traditional karyotyping (Table 1)26. CRISPR editing in stem cells induces a p53-dependent DNA damage response and, through unconscious selection, can enrich for surviving cells carrying oncogenic p53 mutations27,28.
After genome engineering in iPSCs, derivation of monoclonal lineages can take ~14 passages, spanning approximately two months24. Such an essential cloning step poses an extreme genetic bottleneck on cell populations. Cells with unintended de novo genetic changes might be selected as founders of new monoclonal lineages, posing major risks for ongoing experimentation (Fig. 2b,c)25,26. To protect against these, multiple engineered cells should be characterized genetically and phenotypically to ensure that at least several clonal lineages are representative of the original cell line29. This is a good practice for both engineered and non-engineered cell cloning.
Subsequently, established cell lineages should be named and can even be published as stand-alone resources in scientific journals. For example, we have recently developed a pluripotent human ESC line (HUES66) with an inducible lentiviral construct to trigger cortical neuron differentiation24. After verifying pluripotency and normal karyotype, we named the new CRISPR-engineered cell lineage and registered it in a database (hPSCreg)30.
Despite the advantages of registering cell lines in searchable databases, such as the ability to search for particular cell lines or lineages quickly, currently this is not standard practice. Going forward, it will be important to understand impediments that prevent wider use of cell-line databases. A repository for cell-line and -lineage sharing would be transformative as the number of engineered cell lineages continues to grow rapidly.
In summary, there is an urgent need to monitor cell-line genetic identity and stability routinely. In the long-term, lineage tracking can increase research efficiency, enhance the breadth of insights gleaned from experiments, and improve the ease of meeting publication requirements for documenting the cell lines and methods used. Most importantly, it can lead to more reproducible science (Table 1). Above all, documenting daily cell-line management routines and being cognizant of cell-line provenance and lineage formation is an important facet of improving experiment reproducibility and interpretability.
Acknowledgments
We thank L.M. de Buy Wenniger and T. Joseph for valuable feedback on the manuscript and K. White for assistance with graphic design. S.Z. is supported by the Jacobs Technion-Cornell Institute, the Elisha M. Friedman Postdoctoral Fellowship, and FIND Genomics. S.C.G. is supported by a fellowship from the Gordon and Betty Moore Foundation/Life Sciences Research Foundation through Grant GBMF2550.06. N.E.S. is supported by the National Institutes of Health (NIH)/National Human Genome Research Institute (grant no. DP2HG010099), NIH/National Cancer Institute (grant no. R01CA218668), NIH/National Institute of General Medical Sciences (grant no. R01GM138635), the Defense Advanced Research Projects Agency (grant no. D18AP00053), the Sidney Kimmel Foundation, Melanoma Research Alliance, Brain and Behavior Foundation and Cancer Research Institute, and New York University and New York Genome Center startup funds. The authors acknowledge many excellent studies on clonal hematopoiesis, cell lineage formation, cell culture, and genome engineering that could not be cited in this manuscript due to space limitations.
Footnotes
Competing interests
S.Z. is the founder of FIND Genomics, a company that aims to improve reproducible cell-based science and develops cell lineage tracking software. N.E.S is an advisor to Vertex.
References
- 1.Hughes P, Marshall D, Reid Y, Parkes H & Gelber C The costs of using unauthenticated, over-passaged cell lines: how much more data do we need? Biotechniques 43, 575, 577–8, 581–2 passim (2007). [DOI] [PubMed] [Google Scholar]
- 2.Freedman LP, Cockburn IM & Simcoe TS The Economics of Reproducibility in Preclinical Research. PLoS Biol. 13, e1002165 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Liu Y et al. Multi-omic measurements of heterogeneity in HeLa cells across laboratories. Nat. Biotechnol 37, 314–322 (2019). [DOI] [PubMed] [Google Scholar]
- 4.Lin Y-C et al. Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations. Nat. Commun 5, 4767 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Ben-David U et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature 560, 325–330 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Boyer S, Hérissant L & Sherlock G Adaptation is influenced by the complexity of environmental change during evolution in a dynamic environment. PLoS Genet. 17, e1009314 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Nguyen Ba AN et al. High-resolution lineage tracking reveals travelling wave of adaptation in laboratory yeast. Nature 575, 494–499 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Myles S et al. Genetic structure and domestication history of the grape. Proc. Natl. Acad. Sci. U. S. A 108, 3530–3535 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Watson CJ et al. The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science 367, 1449–1454 (2020). [DOI] [PubMed] [Google Scholar]
- 10.Forsberg LA et al. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat. Genet 46, 624–628 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Fittall MW & Van Loo P Translating insights into tumor evolution to clinical practice: promises and challenges. Genome Med. 11, 20 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Malm M et al. Evolution from adherent to suspension: systems biology of HEK293 cell line development. Sci. Rep 10, 18996 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Dumont J, Euwart D, Mei B, Estes S & Kshirsagar R Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Crit. Rev. Biotechnol 36, 1110–1122 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Lund RJ, Närvä E & Lahesmaa R Genetic and epigenetic stability of human pluripotent stem cells. Nat. Rev. Genet 13, 732–744 (2012). [DOI] [PubMed] [Google Scholar]
- 15.Taapken SM et al. Karotypic abnormalities in human induced pluripotent stem cells and embryonic stem cells. Nat. Biotechnol 29, 313–314 (2011). [DOI] [PubMed] [Google Scholar]
- 16.Weissbein U et al. Genome-wide Screen for Culture Adaptation and Tumorigenicity-Related Genes in Human Pluripotent Stem Cells. iScience 11, 398–408 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Barbaric I et al. Time-lapse analysis of human embryonic stem cells reveals multiple bottlenecks restricting colony formation and their relief upon culture adaptation. Stem Cell Reports 3, 142–155 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Bai Q et al. Temporal analysis of genome alterations induced by single-cell passaging in human embryonic stem cells. Stem Cells Dev. 24, 653–662 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Sharma SV, Haber DA & Settleman J Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat. Rev. Cancer 10, 241–253 (2010). [DOI] [PubMed] [Google Scholar]
- 20.Yamamoto H et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 68, 6913–6921 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Komor AC, Badran AH & Liu DR CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes. Cell 168, 20–36 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Chen S et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160, 1246–1260 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Richardson CD, Ray GJ, DeWitt MA, Curie GL & Corn JE Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat. Biotechnol 34, 339–344 (2016). [DOI] [PubMed] [Google Scholar]
- 24.Lu C & Sanjana NE Generation of a knock-in MAP2-tdTomato reporter human embryonic stem cell line with inducible expression of NEUROG2/1 (NYGCe001-A). Stem Cell Res. 41, 101643 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Kosicki M, Tomberg K & Bradley A Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat. Biotechnol 36, 765–771 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Przewrocka J, Rowan A, Rosenthal R, Kanu N & Swanton C Unintended on-target chromosomal instability following CRISPR/Cas9 single gene targeting. Ann. Oncol 31, 1270–1273 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Ihry RJ et al. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat. Med 24, 939–946 (2018). [DOI] [PubMed] [Google Scholar]
- 28.Haapaniemi E, Botla S, Persson J, Schmierer B & Taipale J CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat. Med 24, 927–930 (2018). [DOI] [PubMed] [Google Scholar]
- 29.Kimberland ML et al. Strategies for controlling CRISPR/Cas9 off-target effects and biological variations in mammalian genome editing experiments. J. Biotechnol 284, 91–101 (2018). [DOI] [PubMed] [Google Scholar]
- 30.Isasi R, Namorado J, Mah N, Bultjer N & Kurtz A A pathway for attesting ethical provenance of cell lines: Lessons from the European human pluripotent stem cell registry (hPSCreg). Stem Cell Res. 40, 101539 (2019). [DOI] [PubMed] [Google Scholar]


